Key facts
- TPG is exploring the sale of its healthcare software company, Lyric.
- The potential valuation for Lyric is approximately $5 billion.
- Lyric assists insurers like UnitedHealth, CVS, and Humana in managing medical claims.
- TPG is working with JPMorgan Chase on the sale process.
- The company generates around $250 million in annual EBITDA.
Private equity firm TPG is considering the sale of its healthcare software company, Lyric, in a process that could value the business at approximately $5 billion. This move occurs as the software dealmaking landscape shows signs of recovery following earlier concerns about artificial intelligence's disruptive potential. Lyric, which was acquired by TPG in 2022 as ClaimsXten for $2.2 billion and rebranded the following year, provides services to insurers such as UnitedHealth, CVS, and Humana to identify and prevent inaccurate medical claims payments. TPG is reportedly working with investment bankers at JPMorgan Chase on the potential sale. The company generates about $250 million in annual EBITDA, which, at a typical 20 times multiple, would support a $5 billion valuation. Despite the company's reported acceleration in revenue growth, partly attributed to AI deployment, prospective buyers are assessing the risk of AI-native competitors offering similar functions more cheaply. This uncertainty is reflected in the market, with smaller peer Claritev experiencing a significant stock decline due to AI disruption fears.